title: [Primary amyloidosis].
authors.affiliation: Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España.
authors.forename: Verónica
authors.initials: V
authors.lastname: González de la Calle
authors.affiliation: Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España. Electronic address: rgarcias@usal.es.
authors.forename: Ramón
authors.initials: R
authors.lastname: García-Sanz
authors.affiliation: Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España.
authors.forename: María Victoria
authors.initials: MV
authors.lastname: Mateos
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000075363:Immunoglobulin Light-chain Amyloidosis / Q000175:diagnosis* / Q000628:therapy*; D008558:Melphalan / Q000627:therapeutic use; D016377:Organ Transplantation; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D000074322:Antineoplastic Agents, Immunological; D008558:Melphalan